Head-to-head evidence
JX09 vs VB19055
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertension
Shared mechanism: Aldosterone synthase (CYP11B2) · full Hypertension pipeline
JX09
Developed by Ji Xing Pharmaceuticals (CORXEL)
NCT06183671 · Phase 1 · status unknown
This is a randomized, blinded, placebo-controlled phase 1 study in 92 healthy volunteers testing single and multiple ascending doses of JX09, with safety and tolerability as the primary focus rather than a disease efficacy measure. Results have not been posted.
VB19055
Developed by Yangli Pharmaceutical Technology
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT07833098 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: JX09's landscape · VB19055's landscape